Though long-time survivors could not be generated by ICB treatment when therapy was done in the absence of T cells, the survival times were still significantly prolonged as compared with untreated mice (figure 3D)

Though long-time survivors could not be generated by ICB treatment when therapy was done in the absence of T cells, the survival times were still significantly prolonged as compared with untreated mice (figure 3D). effect was dependent on cytokine-induced senescence in malignant B cells. The proinflammatory cytokines interferon- (IFN-) and tumor necrosis factor (TNF) were necessary for the survival benefit as well as for senescence induction in the -MYC model. Antibody therapy improved T-cell functions such as cytokine production, and long-time survivors were only observed in the presence of T cells. Yet, NK cells also had a pronounced effect on therapy-induced delay of tumor growth. Antibody treatment enhanced numbers, proliferation and IFN- expression of NK cells in developing tumors. The therapeutic effect was fully abrogated only after depletion of both, T cells and NK cells, or after ablation of either IFN- or TNF. Conclusions Tumor cell senescence may explain why patients responding to immune checkpoint blockade frequently show stable growth arrest of tumors rather than complete tumor regression. In the lymphoma model studied, successful therapy required both, tumor-directed T-cell responses and NK cells, which control, at AS703026 (Pimasertib) least partly, tumor development through cytokine-induced tumor senescence. oncogene under the control of the B cell-specific immunoglobulin enhancer. These animals spontaneously develop malignancies, which are located in spleen and lymph nodes and mimic several features of human Burkitt lymphoma.15 Clinical symptoms of tumor growth become visible about 60 to 130 days after birth. In earlier disease stages, proliferation of malignant cells remains clinically undetectable. As soon as clinical symptoms appear, tumor masses grow so rapidly that mice have to be euthanized immediately and therapy cannot be started any more. Therefore, -MYC mice received a combined treatment with anti-CTLA-4 and anti-PD-1 mAbs starting before outgrowth of detectable tumor burdens. Under treatment, (1) tumors developed significantly later and (2) up AS703026 (Pimasertib) to 30% of mice even remained tumor-free for 200 days or survived indefinitely (figure 1), as shown recently.12 Both effects were completely abrogated when either IFN–depleting or TNF-depleting mAbs were given during therapy (figure 1). As shown before by using immunohistology, the tumors are infiltrated by T and B cells and other immune cells. However, the organ architecture is completely destroyed in diseased animals, whereas lymphoid organs from ICB-treated mice that remain healthy show a normal distribution of T and B cells and other immune cells.12 Open in a separate window Figure 1 Effect of ICB therapy on tumor growth in -MYC mice. Animals received anti-PD-1 and anti-CTLA-4 mAbs as described in the methods section or were left untreated. Other groups were additionally injected with IFN–neutralizing and TNF-neutralizing mAbs during therapy. Up to 15 mice were included in each group. For P values see Materials and methods section. CTLA-4, cytotoxic T lymphocyte-associated protein-4; ICB, immune checkpoint blockade; IFN-, interferon-; PD-1, programmed cell death protein 1. By immunohistochemical staining of markers like SA–gal and p16Ink4a in combination with Ki67, p21Cip1, pHP1 and H3K9me3 (tri- methylated lysine residue 9 of Rabbit Polyclonal to RAD17 the histone H3 protein, which is a senescence marker), we previously showed that IFN- and TNF can induce senescence, that is, stable growth arrest of malignant cells via the p16Ink4a and p21 pathway.12 Accordingly, ICB therapy did not confer a significant survival benefit in p21-deficient MYC mice.12 To study the cellular networks involved in ICB-mediated senescence induction in malignant B cells, we now applied a novel approach that relies on flow cytometric detection of intracellular SA–gal activity (figure 2A).18 19 During combined AS703026 (Pimasertib) anti-CTLA-4/anti-PD-1 therapy, the frequency of senescent B cells significantly increased in spleens of tumor-developing mice (figure 2B), which confirmed the results obtained by immunohistochemistry. Like the ICB-induced survival prolongation of.